In Houston, a three-year-old boy whose liver cancer had spread to his lungs and bones—and returned after surgery and chemotherapy—entered an early human trial and emerged, twelve months later, without a trace of disease. The treatment, a form of CAR T cell therapy genetically engineered to hunt a protein found on liver cancer cells, had previously shown its power only against cancers of the blood. That it worked here, against a solid tumor in a small child, does not yet rewrite the map of pediatric oncology—but it marks, quietly and unmistakably, a new coordinate on it.
Experimental CAR T Therapy Achieves Complete Remission in Child With Metastatic Liver Cancer
A 3-year-old child with metastatic liver cancer achieved complete disease remission after experimental treatment, avoiding further chemotherapy and surgery.